Multifunctional Nanotherapeutic System for Advanced Prostate Cancer
Abstract
The main goal of this study is to overcome docetaxel (DTX) resistance in prostate cancer cells by combined delivery of eIF4E siRNA and DTX using dendrimer as a nanocarrier. To this end the objective of this study is to prepare, characterize and test the ability of the combination delivery approach in-vitro in DTX sensitive and resistant prostate cancer cells. We have prepared and characterized the multifunctional delivery system by conjugating DTX to dendrimer and complexing eIF4E siRNA to the resulting conjugate. The DTX-dendrimer conjugate formed complex with siRNA at 20:1 ratio. The dendrimersiRNA complex was taken up by the prostate cancer cells while the free siRNA was not taken up by prostate cancer cells. The siRNA-dendrimer complex showed gene silencing effect in drug sensitive prostate cancer cells. The IC50 of DTX in sensitive prostate cancer cells was found to be 50nm. The pre-treatment of the cells with siRNA followed by DTX treatment slightly in enhanced cell death of prostate cancer cells. Our future studies will focus on developing DTX resistant prostate cancer cells and testing the combination therapeutic approach in the resistant cell lines.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA567963
Entities
People
- Omathanu Perumal
Organizations
- South Dakota State University